International League Against Epilepsy

Epilepsia Report

Executive Summary

The 2004 year was successful for Epilepsia in several regards. We received more manuscript submissions than in prior years with the current editor, totaling 971. The mechanics of the editorial process and journal production have continued to improve, with fewer editorial, publication and circulation errors. Every issue has been printing within its cover month, usually early in the month.

Robert S. Fisher
Editor-in-Chief

Elizabeth Durzy
Journal Publishing Manager

Editorial Issues

Impact Factor

* Data in this report is taken from the 2003 ISI Journal Citation Reports®. This data should be considered confidential material for internal use only and may not be distributed or published in any way.

The Journal’s Impact Factor increased from 3.21 in 2001, to 3.53 in 2002, to 3.55 in 2003.
Epilepsia continues to move up in the Clinical Neurology Journal Rankings, from 15th in 2001, to 14th in 2002, to 13th in 2003.

Robert S. Fisher

Elizabeth Durzy

	Clinical Neurology Journal Rank 2003 Top 20 in of 135	2003 Impact Factor
1	Brain	7.97
2	Ann Neurol	7.72
3	Neurology	5.68
4	Neurosci Biobehav Res	5.48
5	Stroke	5.23
6	J Neuropath Exp Neurol	5.01
7	Arch Neurol	4.68
8	Pain	4.56
9	Int J Neuropsychology	4.00
10	Current Opinion Neurol	3.92
11	Brain Pathology	3.84
12	Bipolar Disorders	3.66
13	Epilepsia	3.55
14	Sleep	3.54
15	Mental Retard Dev Dis	3.48
16	Neuro-Oncology	3.37
17	Lancet Neurology	3.07
18	J Neurol Neurosurg Psych	3.04
19	Neurogenetics	3.03
20	Neuropath Applied Neuro	3.02

-----------------------------------------------------------------------------------

Volume

In 2004, we received 714 manuscripts.

From 1/1/04 - 11/9/04: Year to date decisions

Fisher = 421
Moshe = 191
Perucca = 157
Jackson = 68
Seratosa = 46
MacLaghlan = 4
Bergey = 1

Time from submission to decision:

2001 = 77 days
2002 = 55 days
2003 = 46 days
2004 (YTD) = 38 days

Acceptance by Country (1/20 - 11/04), Sorted by Total

Country	Accepted	Rejected	Revision	Total	Accept Rate
Total	846	1251	1048	3145	26.9%
USA	290	260	325	875	33.1%
Germany	74	70	91	235	31.5%
Italy	57	80	83	220	25.9%
Japan	41	99	63	203	20.2%
Canada	61	53	59	173	35.3%
UK	45	53	53	151	29.8%
France	37	27	55	119	31.1%
Brazil	17	63	26	106	16.0%
Netherlands	30	33	33	98	30.6%
Turkey	11	54	19	84	13.1%
Korea , Rep	14	40	20	74	18.9%
Australia	20	25	21	66	30.3%
India	6	43	11	60	10.0%
Taiwan	12	25	21	58	20.7%
Spain	4	32	6	42	9.5%
Switzerland	11	14	15	40	27.5%
Finland	9	16	14	39	23.1%
Israel	9	18	11	38	23.7%
Hungary	11	15	10	36	30.6%
Austria	5	19	10	34	14.7%
Sweden	10	15	7	32	31.3%
Poland	8	9	13	30	26.7%
China	3	18	4	25	12.0%
Czech Rep	5	10	8	23	21.7%
Mexico	3	12	6	21	14.3%
Iran	3	13	4	20	15.0%
Belgium	2	11	6	19	10.5%
Argentina	1	14	1	16	6.3%
Norway	4	7	4	15	26.7%
Hong Kong	2	11	1	14	14.3%
Portugal	2	5	5	12	16.7%
Egypt	3	4	5	12	25.0%
Singapore	0	8	2	10	0.0%
Greece	2	7	1	10	20.0%
Denmark	1	5	4	10	10.0%
Lebanon	2	5	1	8	25.0%
Yugoslavia	2	3	1	6	33.3%
Jordan	1	3	2	6	16.7%
Oman	0	4	1	5	0.0%
New Zealand	2	1	2	5	40.0%
Scotland	1	2	1	4	25.0%
Russia	2	2	0	4	50.0%
Colombia	1	1	2	4	25.0%

Acceptance by Country, Sorted by Acceptance Rate
(for Countries with at least 25 submissions)

Country	Accepted	Rejected	Revision	Total	Accept Rate
Total	846	1251	1048	3145	26.9%
Canada	61	53	59	173	35.3%
USA	290	260	325	875	33.1%
Germany	74	70	91	235	31.5%
Sweden	10	15	7	32	31.3%
France	37	27	55	119	31.1%
Netherlands	30	33	33	98	30.6%
Hungary	11	15	10	36	30.6%
Australia	20	25	21	66	30.3%
UK	45	53	53	151	29.8%
Switzerland	11	14	15	40	27.5%
Poland	8	9	13	30	26.7%
Italy	57	80	83	220	25.9%
Israel	9	18	11	38	23.7%
Finland	9	16	14	39	23.1%
Taiwan	12	25	21	58	20.7%
Japan	41	99	63	203	20.2%
Korea, Rep	14	40	20	74	18.9%
Brazil	17	63	26	106	16.0%
Austria	5	19	10	34	14.7%
Turkey	11	54	19	84	13.1%
China	3	18	4	25	12.0%
India	6	43	11	60	10.0%
Spain	4	32	6	42	9.5%

---------------------------------------------------------------------------------

Note: The citation count below is a year old, because this year’s is not yet available

Appendix A - Top 50 Articles Accessed via Synergy

Rank	Acc.	Article	Author	Year	Vol.	Iss.	Pg.
1	678	The Importance of Drug Interactions in Epilepsy Therapy	Philip N. Patsalos, Walter Froumlscher, Francesco Pisani, Clementina M. van Rijn	2002	43	4	365
2	529	GABAergic Mechanisms in Epilepsy	David M. Treiman	2001	42	s3	8
3	520	Adolescent Seizures and Epilepsy Syndromes	James W. Wheless, Howard L Kim	2002	43	s3	33
4	502	Epileptic Syndromes in Childhood: Clinical Features, Outcomes, and Treatment	Peter Camfield, Carol Camfield	2002	43	s3	27
5	444	Genetics of the Epilepsies	Samuel F. Berkovic, Ingrid E. Scheffer	2001	42	s5	16
6	438	Neonatal Seizures and Syndromes	Barry R. Tharp	2002	43	s3	2
7	429	American Epilepsy Society Proceedings	null	2002	43	s7	1
8	427	Treatment of Refractory Status Epilepticus with Pentobarbital, Propofol, or Midazolam: A Systematic Review	Jan Claassen, Lawrence J. Hirsch, L Ronald G. Emerson, Stephan A. Mayer	2002	43	2	146
9	424	Is It Status?	Richard P. Brenner	2002	43	s3	103
10	384	A Proposed Diagnostic Scheme for People with Epileptic Seizures and with Epilepsy: Report of the ILAE Task Force on Classification and Terminology	Jerome Engel Jr.	2001	42	6	796
11	379	Cognitive and Behavioral Effects of Epilepsy Treatment	David W. Loring, Kimford J. Meador	2001	42	s8	24
12	340	Generalized Epileptic Disorders: An Update	Massimo Avoli, Michael A. Rogawski, Giuliano Avanzini	2001	42	4	445
13	333	Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy	Stephen M. Dombrowski, Shailesh Y. Desai, Matteo Marroni, Luca Cucullo, Kris Goodrich, William Bingaman, Marc R. Mayberg, Ljiljana Bengez, Damir Janigro	2001	42	12	1501
14	328	Chromosomal Abnormalities and Epilepsy: A Review for Clinicians and Gene Hunters	Rita Singh, R. J McKinlay Gardner, Kathryn M. Crossland, Ingrid E. Scheffer, Samuel F. Berkovic	2002	43	2	127
15	307	null	null	2001	42	s7	1
16	306	Functional MRI of Language Processing: Dependence on Input Modality and Temporal Lobe Epilepsy	A. Carpentier, K. R. Pugh, M. Westerveld, C. Studholme, O. Skrinjar, J.L. Thompson, D. D. Spencer, R.T. Constable	2001	42	10	1241
17	306	Infantile Seizures and Epilepsy Syndromes	Douglas R. Nordli Jr.	2002	43	s3	11
18	305	Neural Networks in Human Epilepsy: Evidence of and Implications for Treatment	Susan S. Spencer	2002	43	3	219
19	295	Children Versus Adults: Pharmacokinetic and Adverse-Effect Differences	Gail D. Anderson	2002	43	s3	53
20	294	Epileptic Encephalopathy	Olivier Dulac	2001	42	s3	23
21	286	The Challenge of Treatment Selection for Epilepsy	Edward Faught, John M. Pellock	2001	42	s8	4
22	283	Epilepsy Surgery in Childhood	J. Helen Cross	2002	43	s3	65
23	281	Advances in Neuroimaging: Surgical Localization	Gregory D. Cascino	2001	42	1	3
24	277	Potassium Channels: How Genetic Studies of Epileptic Syndromes Open Paths to New Therapeutic Targets and Drugs	Edward C. Cooper	2001	42	s5	49
25	276	Channelopathies: Episodic Disorders of the Nervous System	Louis J. Ptacek, Ying-Hui Fu	2001	42	s5	35
26	262	Special Needs of the Adolescent with Epilepsy	Douglas R. Nordli Jr.	2001	42	s8	10
27	261	Basic Mechanisms of Psychotropic Drugs	Ulrich Ebert	2002	43	s2	2
28	258	Voltage-gated Sodium Channels in Epilepsy	Ruumldiger Koumlhling	2002	43	11	1278
29	257	Is Refractory Epilepsy Preventable?	Santiago Arroyo, Martin J. Brodie, Giuliano Avanzini, Christoph Baumgartner, Catherine Chiron, Olivier Dulac, Jacqueline A. French, José M. Serratosa	2002	43	4	437
30	254	Treatment of Benign Epilepsy Syndromes Throughout Life	L. James Willmore	2001	42	s8	6
31	250	Gabapentin versus Lamotrigine Monotherapy: A Double-blind Comparison in Newly Diagnosed Epilepsy	Martin J. Brodie, David W. Chadwick, Henning Anhut, Andreas Otte, Silke-Lo Messmer, Stephen Maton, Wilhelm Sauermann, Guta Murray, Elizabeth A. Garofalo	2002	43	9	993
32	249	The Management of Refractory Idiopathic Epilepsies	Emilio Perucca	2001	42	s3	31
33	244	Effectiveness of First Antiepileptic Drug	Patrick Kwan, Martin J. Brodie	2001	42	10	1255
34	241	Placebos, Placebo Effect, and the Response to the Healing Situation: The Evolution of a Concept	Yiannis G. Papakostas, Michael D. Daras	2001	42	12	1614
35	239	Pregnancy Registries in Epilepsy	Ettore Beghi, John F. Annegers	2001	42	11	1422
36	238	Intractable Epilepsy: Definition and Neurobiology	Jerome Engel Jr.	2001	42	s6	3
37	238	Continuous EEG Monitoring in the Intensive Care Unit	Mark L. Scheuer	2002	43	s3	114
38	237	Cell Death and Synaptic Reorganizations Produced by Seizures	Yehezkel Ben-Ari	2001	42	s3	5
39	236	Chronic Anterior Thalamus Stimulation for Intractable Epilepsy	Mojgan Hodaie, Richard A. Wennberg, Jonathan O. Dostrovsky, Andres M. Lozano	2002	43	6	603
40	231	Carbamazepine versus Valproate Monotherapy for Epilepsy: A Meta-analysis	Anthony G. Marson, Paula R. Williamson, Helen Clough, Jane L. Hutton, David W. Chadwick, on behalf of the Epilepsy Monotherapy Trial Group	2002	43	5	505
41	227	Genetic Identifiers of Epilepsy	Sunao Kaneko, Hiroto Iwasa, Motohiro Okada	2002	43	s9	16
42	225	Levetiracetam Psychosis in Children with Epilepsy	Eric H. Kossoff, Gregory K. Bergey, John M. Freeman, Eileen P. G. Vining	2001	42	12	1611
43	221	Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs	Edoardo Spina, Emilio Perucca	2002	43	s2	37
44	218	Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open-label Trial	Tracy A. Glauser, John M. Pellock, E. Martina Bebin, Nathan B. Fountain, Frank J. Ritter, Christof M. Jensen, W. Donald Shields	2002	43	5	518
45	218	Impact of Pediatric Epilepsy on the Family: A New Scale for Clinical and Research Use	Carol Camfield, Lynn Breau, Peter Camfield	2001	42	1	104
46	213	Clinical and Genetic Analysis of a New Multigenerational Pedigree with GEFS+ (Generalized Epilepsy with Febrile Seizures Plus)	Frédérique Gérard, Sandrine Pereira, Andrée Robaglia-Schlupp, Pierre Genton, Pierre Szepetowski	2002	43	6	581
47	212	Preliminary Results on Pregnancy Outcomes in Women Using Lamotrigine	Patricia Tennis, R. R. Eldridge	2002	43	10	1161
48	210	Alcohol and Marijuana: Effects on Epilepsy and Use by Patients with Epilepsy	Elisabeth Gordon, Orrin Devinsky	2001	42	10	1266
49	209	Effects of Antiepileptic Drugs on Cognition	Albert P. Aldenkamp	2001	42	s1	46
50	207	Modeling Human Epilepsies in Mice	Jeffrey L. Noebels	2001	42	s5	11

Circulation

Total circulation is up over the same period last year by 27%.
Society subscriptions (mainly AES) have increased 13%, while individual and institutional
subscriptions have decreased 8% and 12% respectively.
Online Only subscriptions increased 56% over the same period last year.
Ortho-McNeil is sponsoring the distribution of Epilepsia to 1500 AAN residents in 2004, while Novartis is sponsoring the distribution of Epilepsia to another 400 AAN residents.
Epilepsia has 2519 consortia subscriptions through September 2004.

Circ. Table 1.
Total Circulation through October 31, 2004

Subscriber Type	October 2004	October 2003	% Difference
Society
US	2,242	1947	15%
Canada/Mexico	130	114	14%
Rest of World	572	537	7%
Total Society	2,944	2,598	13%

Individuals
US	37	43	-14%
Canada/Mexico*	1	2	-50%
Rest of World	156	165	-5%
Total Individuals	194	210	-8%

Institutions
US	182	205	-11%
Canada/Mexico	27	36	-25%
Rest of World	647	736	-12%
Total Institutions	856	977	-12%

Sponsorships
US	1900	800	138%
Canada/Mexico	0	0	-
Rest of World	0	13	-100%
Total Sponsorship	1900	813	134%
Complimentary	289	260	11%
GRAND TOTAL	6,183	4,858	27%

Production

Journal has published within 4 business days of the scheduled mail date (often prior to the scheduled mail date) 80% of the time. Issues always mailed within month, usually in first week.
For all issues and supplements, the Synergy version of the journal has been available ahead of print in a complete issue format.
Through October, we published a total of 1,358 pages, excluding supplements.
Published 923 supplemental pages through the
October supplement.

Annual page budget -	Editorial: 2016 Total: 2304
Per Issue page budget -	Editorial: 168 Total: 192

The biggest production problems have been transitional problems to off-shore typesetting, e.g., tiny fonts on the covers and some poor figure quality.

Supplements 2004

Photosensitivity - Kasteleijn-Nolst Trenité. Sanofi- Synthelabo
Neurobehavioral disorders in epilepsy - Devinsky - From an AES symposium with an unrestricted grant from GlaxoSmithKline
Japan Epilepsy Society 35th Congress. Completed and in press.
Neuroimaging: Advances and Applications. AES 2003 Annual Course, supported by AES
Catastrophic Epilepsies of Childhood. Glauser - Supported by Eisai
Pregabalin - From Molecule to Medicine - Ben- Menachem, Symposium in the 2003 International Epilepsy Symposium in Portugal, sponsored by Pfizer.
American Epilepsy Society Abstracts.
Sponsored by AES.

	Home \| Contact Info \| Privacy & Security \| © 2008 ILAE